Yi Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yi Huang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Yijie Gao
Department of Joint Surgery and Sports Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
3 shared publications - Yuhao Guo
Department of Medicine, Danbury Hospital, Zucker School of Medicine at Hofstra/Northwell, 24 Hospital Avenue, Danbury, CT, 06810, USA
2 shared publications Bei Qiu
1 shared publicationHong Zhang
Department of Pharmacy, The 956th Hospital of Chinese People’s Liberation Army, Nyingchi, Tibet, China
1 shared publicationKelin He
1 shared publication- Lei Jing
Department of Gastroenterology The Second Affiliated Hospital of Chongqing Medical University Chongqing 400010 China
1 shared publication
Latest Publications
- Open Access
- 18 September 2026
- Published by American Society of Hematology in Blood Advances
FAERS corroborates the BCMA bispecific PML signal
- 18 September 2026
- Published by American Society of Hematology in Blood Advances
Open AccessFAERS corroborates the BCMA bispecific PML signal
- Open Access
- 6 September 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 60
From trial counting to clinical interpretation in a network meta-analysis of first-time anterior shoulder dislocation
- 6 September 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 60
Open AccessFrom trial counting to clinical interpretation in a network meta-analysis of first-time anterior shoulder dislocation
- Open Access
- 14 September 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1226086
Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
Objective: To investigate and analyze the post-marketing adverse event (AE) data of multiple sclerosis (MS) therapeutic drug dalfampridine using the US Food and Drug Administration Adverse Event Reporting System (FAERS) for its clinical safety application.Methods: Use OpenVigil2.1 platform to obtain AE data of dalfampridine from FAERS from February 2010 to September 2022. Match “adverse drug reaction” with preferred term (PT) and system organ class (SOC) according to the Medical Dictionary for Regulatory Activities (MedDRA), then merge the same PT and delete non-AE PT. Positive signals were identified by the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) methods. When AE signals met the criteria of those three methods, they were identified as positive signals.Results: A total of 44,092 dalfampridine-related AE reports were obtained, and 335 AE signals were identified, including 11,889 AE reports. AEs were more common in females and in the 45–65 age group, which is consistent with the epidemiological characteristics of MS. The 335 AE signals involved 21 SOCs, including investigations, infections and infestations, eye disorders, etc. Among the top 20 PTs in signal strength, 10 were associated with abnormal lymphocyte percentage and count, and 5 were associated with abnormal urine tests, some of which were not described in the instruction, such as spinal cord injury cauda equina, haemoglobin urine present, urinary sediment abnormal and so on. The most frequently reported AE signals were urinary tract infection, dizziness, condition aggravated. In addition, 23 AE signals with death outcomes were identified, with an incidence of less than 0.1%.Conclusion: Data mining of FAERS was conducted to analyze the AEs of dalfampridine, and new AE signals were found. This study provides a reference for the safe use of dalfampridine in the treatment of MS.
- 14 September 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1226086
Open AccessPost-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
Objective: To investigate and analyze the post-marketing adverse event (AE) data of multiple sclerosis (MS) therapeutic drug dalfampridine using the US Food and Drug Administration Adverse Event Reporting System (FAERS) for its clinical safety application.Methods: Use OpenVigil2.1 platform to obtain AE data of dalfampridine from FAERS from February 2010 to September 2022. Match “adverse drug reaction” with preferred term (PT) and system organ class (SOC) according to the Medical Dictionary for Regulatory Activities (MedDRA), then merge the same PT and delete non-AE PT. Positive signals were identified by the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) methods. When AE signals met the criteria of those three methods, they were identified as positive signals.Results: A total of 44,092 dalfampridine-related AE reports were obtained, and 335 AE signals were identified, including 11,889 AE reports. AEs were more common in females and in the 45–65 age group, which is consistent with the epidemiological characteristics of MS. The 335 AE signals involved 21 SOCs, including investigations, infections and infestations, eye disorders, etc. Among the top 20 PTs in signal strength, 10 were associated with abnormal lymphocyte percentage and count, and 5 were associated with abnormal urine tests, some of which were not described in the instruction, such as spinal cord injury cauda equina, haemoglobin urine present, urinary sediment abnormal and so on. The most frequently reported AE signals were urinary tract infection, dizziness, condition aggravated. In addition, 23 AE signals with death outcomes were identified, with an incidence of less than 0.1%.Conclusion: Data mining of FAERS was conducted to analyze the AEs of dalfampridine, and new AE signals were found. This study provides a reference for the safe use of dalfampridine in the treatment of MS.
- 12 April 2023
- Published by Springer Nature in International Orthopaedics
- Vol. 47 (6) , 1641-1642
Letter to the editor on “Predictors of muscle necrosis in patients with acute compartment syndrome”
- 12 April 2023
- Published by Springer Nature in International Orthopaedics
- Vol. 47 (6) , 1641-1642
Letter to the editor on “Predictors of muscle necrosis in patients with acute compartment syndrome”
- Open Access
- 27 October 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Effects of acupuncture on neuropathic pain induced by spinal cord injury:a systematic review and meta-analysis
INPLASY2021100107 Effects of acupuncture on neuropathic pain induced by spinal cord injury: a systematic review and meta-analysis Keywords: acupuncture; spinal cord injury; neuropathic pain; meta-a…
- 27 October 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Open AccessEffects of acupuncture on neuropathic pain induced by spinal cord injury:a systematic review and meta-analysis
INPLASY2021100107 Effects of acupuncture on neuropathic pain induced by spinal cord injury: a systematic review and meta-analysis Keywords: acupuncture; spinal cord injury; neuropathic pain; meta-a…